US HB2194 | 2017-2018 | 115th Congress
Status
Spectrum: Partisan Bill (Republican 3-0)
Status: Introduced on April 27 2017 - 25% progression, died in committee
Action: 2017-04-28 - Referred to the Subcommittee on Health.
Pending: House Subcommittee on Health Committee
Text: Latest bill text (Introduced) [PDF]
Status: Introduced on April 27 2017 - 25% progression, died in committee
Action: 2017-04-28 - Referred to the Subcommittee on Health.
Pending: House Subcommittee on Health Committee
Text: Latest bill text (Introduced) [PDF]
Summary
Cigarette Smoking Reduction and Electronic Vapor Alternatives Act of 2017 This bill amends the Federal Food, Drug, and Cosmetic Act to authorize the Food and Drug Administration (FDA) to regulate electronic cigarettes through regulation of e-liquids (solutions used in electronic cigarettes) and personal electronic vaporizers (products that convert e-liquids into inhalable vapor). E-liquids and personal electronic vaporizers are excluded from the definition of tobacco products. The bill sets forth requirements for the sale and manufacturing of e-liquids and personal electronic vaporizers including: (1) prohibiting sales to persons younger than 18, (2) establishing manufacturing standards, and (3) requiring certification of compliance with manufacturing standards. The FDA may prohibit advertising of e-liquids and vaporizers to minors. The Office of E-Liquid and Personal Vaporizer Standards Compliance is created in the FDA's Center for Tobacco Products and Tobacco Harm Reduction. State and local laws on e-liquids and personal electronic vaporizers are preempted by this bill. The FDA shall provide Congress a comparative health risk assessment of tobacco products and other nicotine delivery alternatives and rank them based on morbidity and mortality risk as compared to smoking cigarettes.
Title
Cigarette Smoking Reduction and Electronic Vapor Alternatives Act of 2017
Sponsors
Rep. Duncan Hunter [R-CA] | Rep. Don Bacon [R-NE] | Rep. Walter Jones [R-NC] |
History
Date | Chamber | Action |
---|---|---|
2017-04-28 | House | Referred to the Subcommittee on Health. |
2017-04-27 | House | Referred to the House Committee on Energy and Commerce. |
2017-04-27 | House | Introduced in House |
Subjects
Congressional oversight
Department of Health and Human Services
Drug safety, medical device, and laboratory regulation
Drug, alcohol, tobacco use
Executive agency funding and structure
Federal preemption
Food and Drug Administration (FDA)
Government studies and investigations
Health
Manufacturing
Marketing and advertising
Medical research
Product safety and quality
Retail and wholesale trades
Department of Health and Human Services
Drug safety, medical device, and laboratory regulation
Drug, alcohol, tobacco use
Executive agency funding and structure
Federal preemption
Food and Drug Administration (FDA)
Government studies and investigations
Health
Manufacturing
Marketing and advertising
Medical research
Product safety and quality
Retail and wholesale trades
US Congress State Sources
Type | Source |
---|---|
Summary | https://www.congress.gov/bill/115th-congress/house-bill/2194/all-info |
Text | https://www.congress.gov/115/bills/hr2194/BILLS-115hr2194ih.pdf |